What is the recommended treatment to increase factor VIII and vWF levels in patients with Von Willebrand Disease after delivery?

The recommended treatment to increase factor VIII and von Willebrand factor (vWF) levels in patients with Von Willebrand Disease after delivery is desmopressin (DDAVP). Desmopressin works by stimulating the endothelial cells to release von Willebrand factor and also increases levels of factor VIII in circulation. This is especially important in the postpartum period, where increased bleeding risk can occur due to the physiological changes in blood hemostasis after delivery.

Desmopressin is particularly effective in patients with Type 1 and some variants of Type 2 Von Willebrand Disease, as they have a sufficient store of vWF which can be mobilized in response to the medication. The administration of DDAVP can help control bleeding episodes and improve the overall hemostatic balance during the postpartum recovery phase.

Other options such as vitamin K, fresh frozen plasma, and warfarin do not target the underlying deficiencies seen in Von Willebrand Disease the way DDAVP does. Vitamin K is involved in the synthesis of certain clotting factors but does not directly influence vWF levels. Fresh frozen plasma contains clotting factors but is generally used in more severe bleeding scenarios or specific factor deficiencies rather than for routine management of Von Willebrand Disease. War